{"id":"tiotropium-bromide-powder-for-inhalation","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Cough"},{"rate":"5-10%","effect":"Dysphonia"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dyspnea"}]},"_chembl":{"chemblId":"CHEMBL3545181","moleculeType":"Small molecule","molecularWeight":"490.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by blocking the action of acetylcholine at muscarinic receptors in the lungs, which leads to bronchodilation and improved lung function. This results in improved symptoms and quality of life for patients with COPD.","oneSentence":"Tiotropium bromide is a long-acting muscarinic antagonist that works by relaxing the airway muscles to improve breathing in patients with chronic obstructive pulmonary disease (COPD).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:52.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT07267130","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT06487416","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-06-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":186},{"nctId":"NCT06326671","phase":"PHASE1","title":"A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-02-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":39},{"nctId":"NCT06254664","phase":"PHASE1","title":"Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-10-03","conditions":"COPD","enrollment":116},{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT00239447","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":131},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT03964207","phase":"PHASE4","title":"A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":72},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT05838703","phase":"PHASE2","title":"Tiotropium Handihaler vs. Tiotropium Respimat in COPD","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2023-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT05161156","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium Bromide Inhalation Powder","status":"COMPLETED","sponsor":"Phargentis SA","startDate":"2022-03-24","conditions":"COPD","enrollment":306},{"nctId":"NCT03842839","phase":"NA","title":"Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2018-10-01","conditions":"Airway Remodeling","enrollment":100},{"nctId":"NCT05246046","phase":"PHASE1","title":"Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2022-02-16","conditions":"Healthy Volunteers","enrollment":88},{"nctId":"NCT00662792","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":147},{"nctId":"NCT01176903","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":65},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03137992","phase":"PHASE3","title":"Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2017-11-21","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":377},{"nctId":"NCT02541006","phase":"PHASE4","title":"Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2014-11","conditions":"COPD","enrollment":58},{"nctId":"NCT02988869","phase":"PHASE4","title":"Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2016-08","conditions":"COPD","enrollment":84},{"nctId":"NCT03395002","phase":"PHASE4","title":"Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-22","conditions":"COPD","enrollment":58},{"nctId":"NCT04147572","phase":"NA","title":"Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-11-01","conditions":"Healthy Volunteer, COPD","enrollment":200},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT02566031","phase":"PHASE4","title":"A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-23","conditions":"COPD","enrollment":379},{"nctId":"NCT03976713","phase":"PHASE3","title":"Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2019-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":348},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT03745261","phase":"PHASE3","title":"Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2018-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT01662986","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01663987","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT02172391","phase":"PHASE3","title":"Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":81},{"nctId":"NCT02172443","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT01937390","phase":"","title":"Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":645},{"nctId":"NCT00565266","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2008-05","conditions":"Asthma","enrollment":210},{"nctId":"NCT02799784","phase":"PHASE4","title":"An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-07-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT01395888","phase":"PHASE3","title":"A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":260},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1017},{"nctId":"NCT01899742","phase":"PHASE3","title":"The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":497},{"nctId":"NCT01777334","phase":"PHASE3","title":"The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":905},{"nctId":"NCT01627327","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":623},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT03169504","phase":"PHASE3","title":"Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2017-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":150},{"nctId":"NCT01085045","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":118},{"nctId":"NCT01715311","phase":"PHASE4","title":"Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT01970878","phase":"PHASE3","title":"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":892},{"nctId":"NCT00868231","phase":"PHASE2","title":"Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT01587079","phase":"PHASE2","title":"Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":159},{"nctId":"NCT00999908","phase":"PHASE3","title":"Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT02254174","phase":"PHASE1","title":"Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT02242253","phase":"PHASE2","title":"Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":97},{"nctId":"NCT02238119","phase":"PHASE2","title":"Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":74},{"nctId":"NCT02173691","phase":"PHASE3","title":"Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":584},{"nctId":"NCT02172352","phase":"PHASE2","title":"Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":28},{"nctId":"NCT02172482","phase":"","title":"Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":63127},{"nctId":"NCT02172469","phase":"PHASE3","title":"Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":215},{"nctId":"NCT02172326","phase":"PHASE3","title":"Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":29},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT01222533","phase":"PHASE2","title":"Tiotropium Respimat Pharmacokinetic Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":154},{"nctId":"NCT01072396","phase":"PHASE4","title":"Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":126},{"nctId":"NCT01120691","phase":"PHASE3","title":"Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2224},{"nctId":"NCT00620516","phase":"","title":"Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3008},{"nctId":"NCT00281567","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT00106821","phase":"PHASE4","title":"Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":166},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT01119937","phase":"PHASE3","title":"Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":211},{"nctId":"NCT00929110","phase":"PHASE3","title":"1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1066},{"nctId":"NCT00578968","phase":"PHASE4","title":"Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":36},{"nctId":"NCT00424528","phase":"PHASE4","title":"Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2006-12","conditions":"Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema","enrollment":235},{"nctId":"NCT00239434","phase":"PHASE3","title":"A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":200},{"nctId":"NCT00877383","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1142},{"nctId":"NCT00846586","phase":"PHASE3","title":"Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1134},{"nctId":"NCT00463567","phase":"PHASE2, PHASE3","title":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive","enrollment":2059},{"nctId":"NCT00615459","phase":"PHASE3","title":"A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":169},{"nctId":"NCT00939211","phase":"PHASE2","title":"The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT01307189","phase":"PHASE4","title":"Effects of Tiotropium on Walking Capacity in Patients With COPD","status":"COMPLETED","sponsor":"Laval University","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tiotropium Bromide Powder for Inhalation","genericName":"Tiotropium Bromide Powder for Inhalation","companyName":"Henan University of Traditional Chinese Medicine","companyId":"henan-university-of-traditional-chinese-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiotropium bromide is a long-acting muscarinic antagonist that works by relaxing the airway muscles to improve breathing in patients with chronic obstructive pulmonary disease (COPD). Used for Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}